1.
Management of
Ovarian
Hyperstimulation
Syndrome
By
Dr. A. A. Abudu

2.
Outline
• Introduction
• Epidemiology
• Pathophysiology
• Clinical presentation
• Clinical assessment
• Treatment
• OHSS and pregnancy
• Prevention

3.
Introduction
• Ovarian hyperstimulation syndrome (OHSS)
was first described in 1943 by Rydberg et al.
as a loss of control over the intended
therapeutic stimulation of the ovaries
• In 1951, the first fatal case of OHSS was
reported

4.
Introduction
• Ovarian hyperstimulation syndrome (OHSS)
is an important and potentially fatal
complication of ovulation induction
• Generally self-limiting and varies from mild
to severe life-threatening symptoms that
may require hospital admission in up to
1.9% of all OHSS cases

5.
Introduction
• Mainly associated with multifollicular
response seen with gonadotrophin
stimulation but may also occur following
use of clomiphene citrate, gonadotrophin-
releasing hormone and rarely, spontaneous
conception cycles

6.
Epidemiology
• True incidence is unknown - classification
schemes, underdiagnosis
• Mild OHSS: 20 – 33% of IVF cycles
• Moderate OHSS: 3 – 6%
• Severe OHSS: 0.1 – 2%

7.
Pathophysiology

8.
Pathophysiology of symptoms

9.
Clinical presentation
• OHSS is generally a self-limiting disorder and
symptoms typically resolve spontaneously
within 7 to 10 days
• Can be described as early or late depending
on time of onset of symptoms

10.
Clinical presentation
• Early OHSS occurs within 10 days of hCG
trigger and reflects ovarian response to
exogenous hormone
• Late OHSS occurs more than 10 days after
hCG trigger (≈7 days after ET), response to
endogenous hCG from pregnancy –
prolonged course, risk of severity

11.
Clinical presentation
• Symptoms:
• Abdominal bloating
• Nausea and vomiting
• Abdominal pain
• Abdominal distension
• Weight gain
• Dyspnoea
• Oliguria (or anuria)

12.
Clinical presentation
• Complications:
• Ascites, pleural/pericardial effusions
• Electrolyte abnormalities (Na , K )
• Hypovolemic shock and acute renal failure
• Thromboembolic events and disseminated
intravascular coagulopathy (DIC)
• Ovarian torsion, rupture
• Adult respiratory distress syndrome (ARDS)

13.
Clinical presentation

14.
Clinical presentation
• Differential diagnoses:
• Ovarian cyst accidents (torsion, haemorrhage,
rupture)
• Pelvic infection
• Intra-abdominal haemorrhage
• Ectopic pregnancy
• Appendicitis

15.
Clinical assessment
• History, timing of ovulation induction
• Full systemic examination
• Baseline weight and abdominal girth
• Laboratory investigations – full blood
count, electrolytes, urea and creatinine,
liver function tests, clotting profile
• Imaging – ultrasound scan, chest X-ray

16.
Clinical assessment

17.
Treatment
• Management is generally supportive until
spontaneous resolution occurs
• May require hospitalization for severe to
critical OHSS and moderate OHSS with
poor symptom control

18.
Treatment
• Patient education – vital component
• Discontinue hCG for luteal support,
progesterone may be used
• Avoid strenuous exercise and sexual
intercourse – risk of torsion

19.
Treatment – outpatient care
• Adequate hydration – drink to thirst
• Antiemetics – metoclopramide, cyclizine
• Analgesics – paracetamol, codeine. Avoid
NSAIDs – risk of renal compromise
• Monitoring of care – review every 2-3 days
usually adequate

20.
Treatment – outpatient care
• Symptom monitoring – appearance of new
symptoms or worsening of existing ones
• Daily weight measurement –
>2pounds/day (≈1kg/day)
• Monitoring of urinary output
• Urgent clinical review may be required

21.
Treatment - hospitalisation
• Usually required for severe cases, poor
symptom control, social considerations
• Multidisciplinary care, intensive care
• Mainly analgesics and antiemetics, fluid
management, thromboprophylaxis and
treatment of complications

22.
Treatment - hospitalisation
•Fluid management:
• Oral fluid intake preferable to intravenous
• 2-3L/day of fluid with strict fluid balance
• Urine output >20-30ml/hr
• Avoid worsening third-space fluid shift
• Correction of hypovolaemia, hypotension
and haemoconcentration

23.
Treatment - hospitalisation
• Fluid management:
• Crystalloids – use of physiological saline or
dextrose in normal saline preferred over
ringer’s lactate – hyponatraemia
• Colloids like albumin, mannitol, dextran,
hydroxyethyl starch (HES) may be required
for plasma expansion

24.
Treatment - hospitalisation
•Fluid management:
• Diuretics avoided due to depletion of
intravascular volume. May have a role in
cases of persistent oliguria despite
adequate intravascular volume expansion
and normal intraabdominal pressure
(after paracentesis)

25.
Treatment - hospitalisation
• Paracentesis (ultrasound-guided):
• ascites causing pain, compromised pulmonary
function or oliguria/anuria unresponsive to
appropriate fluid management
• Reduced intraabdominal pressure renal
perfusion
• Intravenous colloid replacement

26.
Treatment - hospitalisation
• Thromboprophylaxis with TED stockings,
low-molecular weight heparin (SC
Enoxaparin 40mg daily) and heparin (SC
5,000 IU 12hourly)
• Treatment of thromboembolism with low-
molecular weight heparins

27.
Treatment - hospitalisation
• Chest tube drainage of significant pleural
effusion that persists after paracentesis
• Surgical intervention – ovarian torsion
• Monitoring of care

28.
Treatment - hospitalisation
• Monitoring of symptoms
• Daily weighing and abdominal girth
measurement
• Vital signs, oxygen saturation – 2-8 hourly
• Daily physical examinations
• Intake/output monitoring

29.
Treatment - hospitalisation
• Serial full blood count, electrolytes, urea
and creatinine – daily
• Liver function tests, clotting profile – as
necessary
• Ultrasound scans, echocardiogram, chest
X-rays – as required

30.
Treatment - hospitalisation

31.
OHSS and pregnancy
• Severe OHSS commonly associated with
pregnancy
• Pregnancy may continue normally despite
OHSS
• No evidence of increased risk of congenital
abnormalities

32.
Prevention
• Begins with identification of patients at-
risk
• Prior history of OHSS
• Young age
• Low BMI
• Polycystic ovarian syndrome (PCOS)
• Use of GnRH-agonists

33.
Prevention
• Increased antral follicle count; ≥ 24
• High anti-Mullerian hormone; ≥ 3.36ng/ml
• Multiple follicles (>14 follicles with diameter of
11mm)
• Rapidly rising serum oestradiol level
• Prevention can be primary or secondary

34.
Prevention – primary
• Reduced dose of gonadotrophins - chronic
low-dose step-up protocol, limited ovarian
stimulation, avoiding FSH on day of hCG
trigger; response monitored with serial
ultrasound scans and serum oestradiol
levels (2,500pg/ml threshold for risk)

35.
Prevention – primary
• Reduced duration of exposure to
gonadotrophins – mild stimulation
protocol (clomiphene, GnRH-antagonists)
• Use of GnRH-antagonist protocols (cf
agonist) for controlled ovarian stimulation

36.
Prevention – primary
• No use of hCG for luteal support
• In-vitro maturation of oocytes
• Use of insulin-sensitizing agents like
metformin in patients with PCOS

37.
Prevention – secondary
• Coasting – withhold further gonadotropin
stimulation and delay hCG administration
until oestradiol levels plateau or decrease
significantly. No reduction in incidence of
moderate and severe OHSS in RCTs. Delay
usually less than 3 days.

38.
Prevention – secondary
• Cycle cancellation – waste of resources,
risk of spontaneous ovulation
• Reduced hCG doses as ovulation trigger –
5,000 IU cf 10,000IU used successfully in
some centres

39.
Prevention – secondary
•Alternative ovulation triggers –
• GnRH-agonists in antagonist-stimulated
cycles – likelihood of clinical pregnancy
lower
• recombinant LH – lower pregnancy rate,
poor cost/benefit ratio

40.
Prevention – secondary
• Cryopreservation of oocytes – prevents
late OHSS and exacerbation of early OHSS
by pregnancy
• Dopamine agonists like cabergoline
reverse VEGF-mediated vascular
permeability. Started on day of hCG trigger
as 0.5mg for 8 days.

41.
Prevention – secondary
• Intravenous albumin, hydroxyethyl starch
(HES) – bind vasoactive agents, increases
plasma oncotic pressure
• GnRH-antagonist salvage – reduction or
plateau of rising oestradiol levels mid-cycle

42.
Prevention

43.
Conclusion
• Ovarian hyperstimulation syndrome is a
mostly iatrogenic and self-limiting disorder
• Good clinical acumen required to diagnose
• Multiple options of prevention available to
reduce incidence and limit severity

44.
References
• Khalid S, Gray T, Hashim SS. Ovarian hyperstimulation
syndrome. InnovAiT: Education and inspiration for general
practice. 2015 Sep 1;8(9):531-8.
• Mahajan N. Ovarian hyperstimulation syndrome. Int J Infertil
Fetal Med. 2013 Sep;4:71-8.
• Onofriescu AL, Luca A, Bors A, HOLICOV M, ONOFRIESCU M,
VULPOI C. Principles of diagnosis and management in the
ovarian hyperstimulation syndrome. Curr Health Sci J. 2013 Jul
1;39:187-92.
• Kaur H. Prevention of Ovarian Hyperstimulation Syndrome.
Journal of Infertility and Reproductive Biology. 2013;1(4):63-8.
• Smith V, Osianlis T, Vollenhoven B. Prevention of Ovarian
Hyperstimulation Syndrome: A Review. Obstetrics and
gynaecology international. 2015 May 14;2015.